1-4 of 4
Shelby Corman
Close
Sort by
Journal Articles

Response to Extracorporeal Photopheresis in Patients with Cutaneous T-Cell Lymphoma: A Retrospective Medical Chart Review

Michael Girardi, Amy G Johnson, Kacie Carlson, Xingyue Huang, Shelby Corman, Patrick Edmundson, Hrishikesh P Kale, Nifasha Rusibamayila, Francine M. Foss
Journal: Blood
Blood (2021) 138 (Supplement 1): 1405.
https://doi.org/10.1182/blood-2021-151116
Published: 2021
Journal Articles

The Direct Medical Costs of Treatment Discontinuation Among Higher-Risk Myelodysplastic Syndrome Patients Receiving Hypomethylating Agents

Namita Joshi, PhD MS, BPharm, Hrishikesh P Kale, PhDMS,BPharm, Shelby Corman, PharmD, MS, BCPS, Kala Hill, Tim Wert, Amer M. Zeidan, MBBS, MHS
Journal: Blood
Blood (2020) 136 (Supplement 1): 17–18.
https://doi.org/10.1182/blood-2020-139642
Published: 2020
Journal Articles

Patterns of Care and Clinical Outcomes in Peripheral T-Cell Lymphoma Patients Receiving First-Line Treatment in Routine Clinical Practice in France and the United Kingdom

Christopher P Fox, MBChB(Hons), MRCP, FRCPath, PhD, Ajibade O Ashaye, MD MBA, MPH, MSc., Ruchit Shah, PhD, Shelby Corman, PharmD, MS, BCPS, Mehul Dalal, PhD, Lorenz Truemper, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3482.
https://doi.org/10.1182/blood-2019-127289
Published: 2019
Journal Articles

Model of the Impact of Delayed Inhibitor Development on Cumulative Breakthrough Bleeds and Costs in Persons with Hemophilia A Receiving Emicizumab Prophylaxis

Robert F. Sidonio, Jr., Anisha Patel, Shelby Corman, Stephen Chaplin, Karina Raimundo
Journal: Blood
Blood (2018) 132 (Supplement 1): 4710.
https://doi.org/10.1182/blood-2018-99-116410
Published: 2018